21.9 C
New York
Thursday, July 3, 2025

Tag: DK0060027142

newssourcecompanyFORcontentinformation1marketbusiness

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions.

ALK’s tablet mod træpollenallergi godkendt til allergivaccination af børn fra fem år

Lægemiddelstyrelsen har netop godkendt Itulazax, den første tabletbaserede allergivaccination til behandling af børn og unge i alderen fem til 17 år med træpollenallergi i Danmark.

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented extensive data on anaphylaxis and paediatric allergy.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDK0060027142

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers